2019年冠状病毒病(COVID-19)
2019-20冠状病毒爆发
荟萃分析
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
医学
重症监护医学
梅德林
内科学
疾病
病毒学
传染病(医学专业)
爆发
政治学
法学
作者
Qian Zheng,Pengfei Ma,Mingwei Wang,Yiwei Chen,Mengyun Zhou,Lan Ye,Zhanhui Feng,Chunlin Zhang
标识
DOI:10.1016/j.jinf.2022.09.027
摘要
We read with interest a recent article reported by Wang Y et al 1. The authors reported a case of COVID-19 rebound in a severe COVID-19 patient during long term (20 days) treatment of Paxlovid. Paxlovid is a recommended treatment for mild-moderate COVID-19 and risk factors for severe disease. With wide-spread use of Paxlovid, there have been case reports of individuals experiencing virologic rebound. Hence, meta-analysis of the efficiency and safety of Paxlovid in patients with COVID-19 is of great importance.
科研通智能强力驱动
Strongly Powered by AbleSci AI